A federal judge sentenced anesthesiologist Dr. Scott Reuben of Springfield, Mass., to six months in prison for fabricating pain management drug test results.
Millipore Corp. (NYSE:MIL) shareholders approved a $7.2 billion merger proposed by German pharmaceutical giant Merck KGaA (NYSE:MRK).
The $107-per-share deal, announced in February, would see Merck take on another $890 million in Millipore debt.
The CEO of a laboratory science company — most likely Thermo Fisher Scientific Inc.’s (NYSE:TMO) Marc Casper — helped set off the bidding contest for Millipore Corp. (NYSE:MIL) when he proposed a cash acquisition of the maker of filters and instruments in a Jan. 4 letter to company officials, according to recent securities documents.
German pharmaceutical and chemical company Merck KGaA (NYSE:MRK) trumped other would-be suitors and struck a deal to acquire Millipore Corp. (NYSE:MIL) for $6 billion in cash plus about $890 million in Millipore debt.
The acquisition was announced early Sunday night by the two companies. At $107 a share, the deal marks just over a 50 percent premium from Millipore’s stock price a week ago, when word leaked that Thermo Fisher Scientific Inc. (NYSE:TMO) was preparing a bid for Millipore.